PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
Compare
ARA-290 vs Pinealon
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
ARA-290
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
4
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Pinealon
20 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Cognition
145
Recovery
145
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
140
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 2 mg (open-ended top bucket)
0.1–0.2 mg
31
0.2–0.4 mg
107
1–2 mg
5
2+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 72% said they felt similar to their last entry, 28% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 105 days · Based on 18 repeat reporters
Sources (7)
Published sources linked on the ARA-290 and Pinealon wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014
- Wiki study page →Source
PubMed
The time to develop treatments for diabetic neuropathy
Rendell MS. Expert opinion on investigational drugs. 2021
- Wiki study page →Source
PubMed
Peptide bioregulators: a new class of geroprotectors
Khavinson VK, Morozov VG. Adv Gerontol. 2006
- Wiki study page →Source
PubMed
Peptide bioregulation of aging: results and prospects
Khavinson VK. Biogerontology. 2009
- Wiki study page →Source
PubMed
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
Khavinson V, Ribakova Y, Kulebiakin K, et al. Rejuvenation research. 2011
- Wiki study page →Source
PubMed
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Khavinson V, Linkova N, Kozhevnikova E, et al. Molecules (Basel, Switzerland). 2020